Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy

Purpose: CD1d-restricted invariant natural killer T (iNKT) cells are important immunoregulatory cells in antitumor immune responses. However, the quantitative and qualitative defects of iNKT cells in advanced multiple myeloma hamper their antitumor effects. Therefore, the development of functional iNKT cells may provide a novel strategy for the immunotherapy in multiple myeloma. Experimental Design: We activated and expanded iNKT cells from multiple myeloma patients with α-galactosylceramide (α-GalCer)-pulsed dendritic cells, characterized their antitumor effects by the cytokine production profile and cytotoxicity against multiple myeloma cells, and explored the effects of immunomodulatory drug lenalidomide on these iNKT cells. We also investigated the expression of CD1d by primary multiple myeloma cells and its function to activate iNKT cells. Results: We established highly purified functional iNKT cell lines from newly diagnosed and advanced multiple myeloma patients. These CD1d-restricted iNKT cell lines produced high level of antitumor Th1 cytokine in response to α-GalCer-pulsed primary multiple myeloma cells, CD1d-transfected MM1S cell line, and dendritic cells. Moreover, iNKT cell lines displayed strong cytotoxicity against α-GalCer-pulsed primary multiple myeloma cells. Importantly, lenalidomide further augmented the Th1 polarization by iNKT cell lines via increased Th1 cytokine production and reduced Th2 cytokine production. We also showed that CD1d was expressed in primary multiple myeloma cells at mRNA and protein levels from the majority of multiple myeloma patients, but not in normal plasma cells and multiple myeloma cell lines, and CD1d+ primary multiple myeloma cells presented antigens to activate iNKT cell lines. Conclusions: Taken together, our results provide the preclinical evidence for the iNKT cell-mediated immunotherapy and a rationale for their use in combination with lenalidomide in multiple myeloma treatment.

[1]  S. Balk,et al.  Natural Killer T Cell–Based Cancer Immunotherapy , 2006, Clinical Cancer Research.

[2]  S. Jagannath,et al.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.

[3]  N. Munshi,et al.  Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. , 2005, Cancer research.

[4]  C. Leemans,et al.  Peripheral blood IFN‐γ‐secreting Vα24+Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load , 2005 .

[5]  M. Kronenberg,et al.  Going both ways: immune regulation via CD1d-dependent NKT cells. , 2004, The Journal of clinical investigation.

[6]  Angus G. Dalgleish,et al.  The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.

[7]  Michael B Brenner,et al.  CD1: antigen presentation and T cell function. , 2004, Annual review of immunology.

[8]  N. Munshi,et al.  Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. , 2004, Blood.

[9]  S. Nimer,et al.  Severe and selective deficiency of interferon‐γ‐producing invariant natural killer T cells in patients with myelodysplastic syndromes , 2003, British journal of haematology.

[10]  D. Vesole.  Transplantation for multiple myeloma: who, when, how often? Patient selection and goals. , 2003, Blood.

[11]  G. Giaccone,et al.  Polarization of Vα24+ Vβ11+ Natural Killer T Cells of Healthy Volunteers and Cancer Patients Using α-Galactosylceramide-loaded and Environmentally Instructed Dendritic Cells , 2003 .

[12]  H. Hirai,et al.  Vα24+ natural killer T‐cell responses against T‐acute lymphoblastic leukaemia cells: implications for immunotherapy , 2003 .

[13]  M. Dhodapkar,et al.  A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma , 2003, The Journal of experimental medicine.

[14]  K. Weinberg,et al.  Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells , 2003, Leukemia.

[15]  D. Vesole,et al.  High-dose therapy in multiple myeloma. , 2003, Blood.

[16]  E. Nieuwenhuis.  CD1d-dependent, macrophage-mediated clearance of Pseudomonas aeruginosa from lung ☆ , 2002 .

[17]  M. Nozue,et al.  Impaired Proliferative Response of Vα24 NKT Cells from Cancer Patients Against α-Galactosylceramide1 , 2002, The Journal of Immunology.

[18]  D. Pellicci,et al.  Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. , 2002, Blood.

[19]  G. Bubley,et al.  Loss of IFN-γ Production by Invariant NK T Cells in Advanced Cancer1 , 2001, The Journal of Immunology.

[20]  R. Seeger,et al.  Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells1 , 2001, The Journal of Immunology.

[21]  G. Morgan,et al.  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. , 2001, Blood.

[22]  Y. Iwakura,et al.  Critical contribution of IFN‐γ and NK cells, but not perforin‐mediated cytotoxicity, to anti‐metastatic effect of α‐galactosylceramide , 2001 .

[23]  H. Macdonald,et al.  Selective Bystander Proliferation of Memory CD4+ and CD8+ T Cells Upon NK T or T Cell Activation , 2000, The Journal of Immunology.

[24]  L. Kaer,et al.  The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. , 2000, International immunology.

[25]  L. Kaer,et al.  Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. , 2000, International immunology.

[26]  H. Macdonald,et al.  Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells , 2000, European journal of immunology.

[27]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[28]  S. Balk,et al.  Requirements for CD1d Recognition by Human Invariant Vα24+ CD4−CD8− T Cells , 1997, The Journal of experimental medicine.

[29]  B. Barlogie,et al.  Graft-versus-myeloma effect: proof of principle. , 1996, Blood.